CancerDrs

Lung Cancer clinical trials in Indiana

28 actively recruiting lung cancer trials at 15 sites across Indiana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Indiana:
  • Northwest Cancer Center - Crown Point — Crown Point, Indiana
  • Northwest Oncology LLC — Dyer, Indiana
  • Northwest Cancer Center - Hobart — Hobart, Indiana
  • Saint Mary Medical Center — Hobart, Indiana
  • The Community Hospital — Munster, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Indiana:
  • IU Health West Hospital — Avon, Indiana
  • IU Health North Hospital — Carmel, Indiana
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Indiana:
  • Goshen Center for Cancer Care — Goshen, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Indiana:
  • Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Franciscan Health — Indianapolis, Indiana
  • Community Cancer Center North — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Indiana:
  • Research Site — Noblesville, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Hematology Oncology of Indiana — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…

Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Indiana:
  • Fort Wayne Medical Oncology - 1133 — Fort Wayne, Indiana
  • Deaconess Chancellor Center for Oncology - 1131 — Newburgh, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Indiana:
  • Research Site — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…

Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Indiana:
  • Parkview Research Center — Fort Wayne, Indiana
  • IU Health Ball Memorial Hospital and Physicians - Cancer Center - Muncie — Muncie, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Indiana:
  • Indiana University Health Arnett Cancer Center ( Site 0116) — Lafayette, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Indiana:
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care trea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05198830
Sites in Indiana:
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the effic…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06773910
Sites in Indiana:
  • Indiana University Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…

Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Indiana:
  • Parkview Comprehensive Cancer Center /ID# 271879 — Fort Wayne, Indiana
  • Community Health Network /ID# 273437 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Indiana:
  • Community Health Network, Inc. — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be rand…

Sponsor: Greg Durm, MD
NCT ID: NCT04317534
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by mainten…

Sponsor: Muhammad Furqan
NCT ID: NCT04699838
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Indiana:
  • UChicago Medicine - Northwest Indiana — Crown Point, Indiana
  • Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
  • Community Health Network, Inc — Indianapolis, Indiana
  • Community Health Network, Inc. — Indianapolis, Indiana
  • Community Health Network Investigational Drug Services — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Indiana:
  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 — Fort Wayne, Indiana
  • Community Health Network, Inc. /ID# 243011 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana:
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
NA Recruiting Federal

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effec…

Sponsor: VA Office of Research and Development
NCT ID: NCT02984761
Sites in Indiana:
  • Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Industry

BostonGene and Exigent Genomic INsight Study

The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, asse…

Sponsor: BostonGene
NCT ID: NCT06272864
Sites in Indiana:
  • Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
View on ClinicalTrials.gov →

Showing 25 of 28 trials with sites in Indiana. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07